Feedback PLC First sale of TexRAD in China (4455Y)
09 September 2015 - 4:00PM
UK Regulatory
TIDMFDBK
RNS Number : 4455Y
Feedback PLC
09 September 2015
9 September 2015
Feedback plc
("Feedback" or the "Company")
First sale of TexRAD in China
Feedback plc (AIM: FDBK), the medical imaging software company,
is pleased to announce the first sale for research purposes of
Feedback's TexRAD texture analysis software in China. Peking Union
Medical College Hospital ("PUMCH"), Beijing, China, has recently
purchased the TexRAD software to undertake research studies in
cancer and other diseases. This has been made possible via
logistical support from GE Healthcare ("GE").
PUMCH is one of the most renowned hospitals in the People's
Republic of China. It was founded in 1921 by the China Medical
Board in New York under the Rockefeller Foundation and is located
in the centre of modern Beijing. PUMCH is committed to delivering
state-of-the-art clinical care, innovative scientific research and
rigorous medical education and it enjoys a high reputation for its
full range of disciplines, leading medical practitioners and
cutting-edge technologies. It is also a national referral centre
for the diagnosis and therapeutic care of complex and rare
disorders.
Dr. Huadan (Danna) Xue, Assistant Professor in the Department of
Radiology, PUMCH commented, "We are very excited with the prospects
of using the TexRAD imaging research software platform in
conjunction with the research and clinical support from GE towards
PUMCH, further reinforcing our vision and reputation of being early
adopters of new technologies, particularly in the fascinating area
of quantitative imaging and its applications in cancer care and
other diseases."
TexRAD research software will extract key heterogeneity
information via a novel quantitative texture analysis approach from
PUMCH's cancer imaging datasets. TexRAD has already established
itself as a leading and innovative texture analysis software
product, currently employed as a research tool in a number of
prestigious imaging centres and university hospitals in the western
world and recently in other large Asian markets such as South Korea
and Japan. Similarly at PUMCH, TexRAD will be assisting to enhance
the research output in cancer and other non-cancer imaging
applications and helping to identify potential clinical
applications to improve care management of patients in the
future.
Dr. Balaji Ganeshan, Chief Scientist and New Business Officer at
the Company's subsidiaries TexRAD Ltd and Cambridge Computed
Imaging Ltd, commented, "We are delighted to receive this order,
working with a leading original equipment manufacturer on the sale
and entering the huge Chinese market. We are especially privileged
to be supplying PUMCH which is recognized to be the leading
hospital in China and working with the Department of Radiology,
headed by the internationally renowned Dr Zheng-Yu Jin. We believe
this will open up new avenues and opportunities for Feedback in
establishing itself and fulfilling its vision as an innovative
multi-modality medical imaging software company."
For further information contact:
Feedback plc Tel: 01954
718072
Simon Barrell / Trevor Brown
/ Tom Charlton
Sanlam Securities UK (Nominated Tel: 020 7628
Adviser and Joint Broker) 2200
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Tel: 020 7469
Ltd (Joint Broker) 0936
Lucy Williams / Duncan Vasey
Notes to editors:
TexRAD (is a novel sophisticated imaging risk stratification
research tool that analyses the textures in existing radiological
scans. This research software application analyses textures,
detecting and measuring tumour heterogeneity (complexity) from
these images, revealing more information from medical images than
it is currently possible to see with the naked eye. Research to
date has shown that TexRAD could potentially assist the clinician
(as an 'Imaging-Biomarker') in confident decision-making: assessing
the prognosis, disease-severity (e.g. risk of metastases) and
response evaluation of patients with cancer. Currently TexRAD
research has shown great potential in many different oncological
sites, including, colorectal, breast, lung, prostate, oesophageal,
head & neck, lymphoma, liver and renal cancers and could
potentially be employed as a heterogeneity assessing tool in the
era of 'Precision and Personalized Medicine'.TexRAD is manufactured
under licence by the ISO 13485 certified company Cambridge Computed
Imaging Ltd, a subsidiary of Feedback plc. More information is
available on www.fbk.com and www.texrad.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUWRSRVWAKRAR
(END) Dow Jones Newswires
September 09, 2015 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
From Sep 2024 to Oct 2024
Feedback (LSE:FDBK)
Historical Stock Chart
From Oct 2023 to Oct 2024